Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT5QSD)

Drug Name

Resimmune Drug Info

Synonyms

A-dmDT390-bisFv immunotoxin

Indication

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting T-cell surface glycoprotein CD3 epsilon (CD3E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Muromonab	DM8ANCF	Organ transplant rejection	NE84	Approved	[4]
Ertumaxomab	DM5Z3VP	Breast cancer	2C60-2C65	Phase 2	[5]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
Autologous T-cell therapy	DMOAET3	Prostate cancer	2C82.0	Phase 1	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD3 epsilon (CD3E)	TTZAT79	CD3E_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038158)
3	Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Haematologica.2015 Jun;100(6):794-800.
4	Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35.
5	Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
6	EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
7	Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.